Swaminathan Padmanabhan Iyer

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

L. Sehn, A. Zelenetz, J. Friedberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive cell therapy for acute myeloid leukemia

S. Parmar, Swaminathan Padmanabhan Iyer, Y. Gong, 2019, Leukemia & lymphoma.

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

C. Reeder, H. Niu, K. McDonagh, 2013, Investigational New Drugs.

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

B. Coiffier, S. Horwitz, H. Prince, 2014, Journal of Hematology & Oncology.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

J. Gribben, I. Flinn, C. Klein, 2019, Blood.

A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma.

E. Shpall, D. Chihara, J. Westin, 2023, Blood advances.